TREX1 loss was significantly associated (log-rank p < 0.05) with worse prognosis in acute myeloid leukemia (OS), bladder urothelial carcinoma (PFS), colorectal cancer (OS and PFS), kidney papillary cell carcinoma (OS and PFS), lower grade glioma (PFS), uterine corpus endometrial carcinoma (OS and PFS), and uveal melanoma (OS and PFS). This evidence concerns the gene TREX1 and uveal melanoma.